Résumé
The evaluation of prognosis is essential for the management of a patient with a neuroendocrine tumor, especially digestive, in which the risk of malignancy is significant. Three validated histoprognostic factors are available from the pathological examination: morphological differentiation status, histological grade, and pTNM stage. Numerous prognostic biomarkers have been proposed in the literature but none has been transposed to clinical practice. In the sameway, among the candidate predictive biomarkers, only MGMT is an emerging biomarker, which may be useful for the prediction of the response to temozolomide.
| Titre traduit de la contribution | Histoprognostic factors in digestive neuroendocrine tumors |
|---|---|
| langue originale | Français |
| Pages (de - à) | 510-514 |
| Nombre de pages | 5 |
| journal | Oncologie |
| Volume | 15 |
| Numéro de publication | 10-11 |
| Les DOIs | |
| état | Publié - 1 oct. 2013 |
| Modification externe | Oui |
mots-clés
- Neuroendocrine tumors
- Predictive biomarkers
- Prognostic factors
- Proliferation indexes